Pharming Group (PHAR)
9.15
+0.22
(+2.46%)
USD |
NASDAQ |
May 31, 16:00
9.105
-0.04
(-0.49%)
After-Hours: 20:00
Pharming Group Enterprise Value: 549.11M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 549.11M |
| May 30, 2024 | 534.30M |
| May 29, 2024 | 557.87M |
| May 28, 2024 | 542.38M |
| May 24, 2024 | 559.89M |
| May 23, 2024 | 542.38M |
| May 22, 2024 | 557.20M |
| May 21, 2024 | 567.97M |
| May 20, 2024 | 539.01M |
| May 17, 2024 | 559.22M |
| May 16, 2024 | 576.05M |
| May 15, 2024 | 578.41M |
| May 14, 2024 | 581.44M |
| May 13, 2024 | 561.91M |
| May 10, 2024 | 606.36M |
| May 09, 2024 | 585.36M |
| May 08, 2024 | 572.69M |
| May 07, 2024 | 583.46M |
| May 06, 2024 | 587.84M |
| May 03, 2024 | 606.36M |
| May 02, 2024 | 606.35M |
| May 01, 2024 | 636.66M |
| April 30, 2024 | 590.87M |
| April 29, 2024 | 600.30M |
| April 26, 2024 | 592.91M |
| Date | Value |
|---|---|
| April 25, 2024 | 636.66M |
| April 24, 2024 | 594.91M |
| April 23, 2024 | 579.42M |
| April 22, 2024 | 600.97M |
| April 19, 2024 | 606.36M |
| April 18, 2024 | 561.24M |
| April 17, 2024 | 617.81M |
| April 16, 2024 | 617.81M |
| April 15, 2024 | 658.89M |
| April 12, 2024 | 642.05M |
| April 11, 2024 | 693.90M |
| April 10, 2024 | 638.68M |
| April 09, 2024 | 606.36M |
| April 08, 2024 | 650.13M |
| April 05, 2024 | 646.76M |
| April 04, 2024 | 652.82M |
| April 03, 2024 | 671.01M |
| April 02, 2024 | 657.54M |
| April 01, 2024 | 692.92M |
| March 31, 2024 | 662.93M |
| March 28, 2024 | 652.44M |
| March 27, 2024 | 652.44M |
| March 26, 2024 | 653.11M |
| March 25, 2024 | 681.30M |
| March 22, 2024 | 681.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
376.23M
Minimum
Jun 16 2022
1.027B
Maximum
Dec 23 2020
662.72M
Average
681.37M
Median
Enterprise Value Benchmarks
| uniQure NV | -214.21M |
| ProQR Therapeutics NV | 53.04M |
| Merus NV | 2.787B |
| argenx SE | 18.88B |
| Pharvaris NV | 634.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.45M |
| Revenue (Quarterly) | 55.59M |
| Total Expenses (Quarterly) | 71.90M |
| EPS Diluted (Quarterly) | -0.19 |
| Gross Profit Margin (Quarterly) | 84.91% |
| Profit Margin (Quarterly) | -22.39% |
| Earnings Yield | -1.75% |
| Normalized Earnings Yield | -1.749 |